Tags

Type your tag names separated by a space and hit enter

Medical marijuana for cancer.
CA Cancer J Clin 2015; 65(2):109-22CC

Abstract

Answer questions and earn CME/CNE Marijuana has been used for centuries, and interest in its medicinal properties has been increasing in recent years. Investigations into these medicinal properties has led to the development of cannabinoid pharmaceuticals such as dronabinol, nabilone, and nabiximols. Dronabinol is best studied in the treatment of nausea secondary to cancer chemotherapy and anorexia associated with weight loss in patients with acquired immune deficiency syndrome, and is approved by the US Food and Drug Administration for those indications. Nabilone has been best studied for the treatment of nausea secondary to cancer chemotherapy. There are also limited studies of these drugs for other conditions. Nabiximols is only available in the United States through clinical trials, but is used in Canada and the United Kingdom for the treatment of spasticity secondary to multiple sclerosis and pain. Studies of marijuana have concentrated on nausea, appetite, and pain. This article will review the literature regarding the medical use of marijuana and these cannabinoid pharmaceuticals (with emphasis on indications relevant to oncology), as well as available information regarding adverse effects of marijuana use.

Authors+Show Affiliations

Medical Editor, American Cancer Society, Atlanta, GA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25503438

Citation

Kramer, Joan L.. "Medical Marijuana for Cancer." CA: a Cancer Journal for Clinicians, vol. 65, no. 2, 2015, pp. 109-22.
Kramer JL. Medical marijuana for cancer. CA Cancer J Clin. 2015;65(2):109-22.
Kramer, J. L. (2015). Medical marijuana for cancer. CA: a Cancer Journal for Clinicians, 65(2), pp. 109-22. doi:10.3322/caac.21260.
Kramer JL. Medical Marijuana for Cancer. CA Cancer J Clin. 2015;65(2):109-22. PubMed PMID: 25503438.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Medical marijuana for cancer. A1 - Kramer,Joan L, Y1 - 2014/12/10/ PY - 2014/12/16/entrez PY - 2014/12/17/pubmed PY - 2015/5/6/medline KW - cannabidiol KW - cannabis KW - marijuana KW - tetrahydrocannabinol SP - 109 EP - 22 JF - CA: a cancer journal for clinicians JO - CA Cancer J Clin VL - 65 IS - 2 N2 - Answer questions and earn CME/CNE Marijuana has been used for centuries, and interest in its medicinal properties has been increasing in recent years. Investigations into these medicinal properties has led to the development of cannabinoid pharmaceuticals such as dronabinol, nabilone, and nabiximols. Dronabinol is best studied in the treatment of nausea secondary to cancer chemotherapy and anorexia associated with weight loss in patients with acquired immune deficiency syndrome, and is approved by the US Food and Drug Administration for those indications. Nabilone has been best studied for the treatment of nausea secondary to cancer chemotherapy. There are also limited studies of these drugs for other conditions. Nabiximols is only available in the United States through clinical trials, but is used in Canada and the United Kingdom for the treatment of spasticity secondary to multiple sclerosis and pain. Studies of marijuana have concentrated on nausea, appetite, and pain. This article will review the literature regarding the medical use of marijuana and these cannabinoid pharmaceuticals (with emphasis on indications relevant to oncology), as well as available information regarding adverse effects of marijuana use. SN - 1542-4863 UR - https://www.unboundmedicine.com/medline/citation/25503438/Medical_marijuana_for_cancer_ L2 - https://doi.org/10.3322/caac.21260 DB - PRIME DP - Unbound Medicine ER -